vs
Side-by-side financial comparison of HIVE Digital Technologies Ltd. (HIVE) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.
HIVE Digital Technologies Ltd. is the larger business by last-quarter revenue ($93.1M vs $57.6M, roughly 1.6× Phathom Pharmaceuticals, Inc.). On growth, HIVE Digital Technologies Ltd. posted the faster year-over-year revenue change (218.6% vs 94.1%).
Mastech Digital, Inc. is a digital transformation and information technology (IT) services company headquartered in Pittsburgh, Pennsylvania, providing services to corporations across North America, Middle East, Asian, and Japan.
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
HIVE vs PHAT — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $93.1M | $57.6M |
| Net Profit | $-91.3M | — |
| Gross Margin | -27.1% | 86.7% |
| Operating Margin | — | — |
| Net Margin | -98.1% | — |
| Revenue YoY | 218.6% | 94.1% |
| Net Profit YoY | -234.0% | 71.6% |
| EPS (diluted) | $-0.38 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $93.1M | $57.6M | ||
| Q3 25 | $87.3M | $49.5M | ||
| Q2 25 | $45.6M | $39.5M | ||
| Q1 25 | — | $28.5M | ||
| Q4 24 | $29.2M | $29.7M | ||
| Q3 24 | $22.6M | $16.4M | ||
| Q2 24 | $32.2M | $7.3M | ||
| Q4 23 | $22.8M | — |
| Q4 25 | $-91.3M | — | ||
| Q3 25 | $-15.8M | $-30.0M | ||
| Q2 25 | $35.0M | $-75.8M | ||
| Q1 25 | — | $-94.3M | ||
| Q4 24 | $68.2M | — | ||
| Q3 24 | $80.0K | $-85.6M | ||
| Q2 24 | $-18.3M | $-91.4M | ||
| Q4 23 | $-24.5M | — |
| Q4 25 | -27.1% | 86.7% | ||
| Q3 25 | 4.7% | 87.5% | ||
| Q2 25 | -13.6% | 87.2% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | -43.7% | 87.1% | ||
| Q3 24 | -66.1% | 85.6% | ||
| Q2 24 | -7.4% | 81.2% | ||
| Q4 23 | -52.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -30.8% | ||
| Q2 25 | — | -151.7% | ||
| Q1 25 | — | -276.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -433.0% | ||
| Q2 24 | — | -1055.4% | ||
| Q4 23 | — | — |
| Q4 25 | -98.1% | — | ||
| Q3 25 | -18.1% | -60.5% | ||
| Q2 25 | 76.8% | -191.9% | ||
| Q1 25 | — | -330.7% | ||
| Q4 24 | 233.2% | — | ||
| Q3 24 | 0.4% | -523.3% | ||
| Q2 24 | -56.7% | -1248.6% | ||
| Q4 23 | -107.8% | — |
| Q4 25 | $-0.38 | — | ||
| Q3 25 | $-0.07 | $-0.41 | ||
| Q2 25 | $0.18 | $-1.05 | ||
| Q1 25 | — | $-1.31 | ||
| Q4 24 | $0.52 | — | ||
| Q3 24 | $0.00 | $-1.32 | ||
| Q2 24 | $-0.17 | $-1.56 | ||
| Q4 23 | $-0.29 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $130.0M |
| Total DebtLower is stronger | — | $209.1M |
| Stockholders' EquityBook value | $559.3M | $-438.2M |
| Total Assets | $624.0M | $259.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $130.0M | ||
| Q3 25 | — | $135.2M | ||
| Q2 25 | — | $149.6M | ||
| Q1 25 | — | $212.3M | ||
| Q4 24 | $40.5M | $297.3M | ||
| Q3 24 | $31.7M | $334.7M | ||
| Q2 24 | — | $276.2M | ||
| Q4 23 | $4.5M | — |
| Q4 25 | — | $209.1M | ||
| Q3 25 | — | $207.1M | ||
| Q2 25 | — | $205.1M | ||
| Q1 25 | — | $203.2M | ||
| Q4 24 | — | $201.4M | ||
| Q3 24 | — | $175.7M | ||
| Q2 24 | — | $174.4M | ||
| Q4 23 | — | — |
| Q4 25 | $559.3M | $-438.2M | ||
| Q3 25 | $624.6M | $-422.5M | ||
| Q2 25 | $560.5M | $-405.8M | ||
| Q1 25 | — | $-338.4M | ||
| Q4 24 | $430.9M | $-253.6M | ||
| Q3 24 | $275.5M | $-187.1M | ||
| Q2 24 | $268.6M | $-233.8M | ||
| Q4 23 | $122.9M | — |
| Q4 25 | $624.0M | $259.1M | ||
| Q3 25 | $693.0M | $240.3M | ||
| Q2 25 | $628.7M | $250.2M | ||
| Q1 25 | — | $294.2M | ||
| Q4 24 | $478.6M | $378.3M | ||
| Q3 24 | $334.7M | $387.0M | ||
| Q2 24 | — | $319.4M | ||
| Q4 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $46.0M | $-166.8M |
| Free Cash FlowOCF − Capex | — | $-167.0M |
| FCF MarginFCF / Revenue | — | -290.0% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-328.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $46.0M | $-166.8M | ||
| Q3 25 | $-10.6M | $-14.1M | ||
| Q2 25 | $10.2M | $-62.7M | ||
| Q1 25 | — | $-84.9M | ||
| Q4 24 | $-28.5M | $-266.8M | ||
| Q3 24 | $-2.2M | $-63.6M | ||
| Q2 24 | $-4.4M | $-70.7M | ||
| Q4 23 | — | — |
| Q4 25 | — | $-167.0M | ||
| Q3 25 | — | $-14.1M | ||
| Q2 25 | — | $-62.8M | ||
| Q1 25 | — | $-84.9M | ||
| Q4 24 | $-55.5M | $-266.9M | ||
| Q3 24 | $-34.7M | $-63.6M | ||
| Q2 24 | — | $-70.8M | ||
| Q4 23 | — | — |
| Q4 25 | — | -290.0% | ||
| Q3 25 | — | -28.6% | ||
| Q2 25 | — | -159.0% | ||
| Q1 25 | — | -297.9% | ||
| Q4 24 | -189.9% | -899.8% | ||
| Q3 24 | -153.4% | -389.0% | ||
| Q2 24 | — | -966.2% | ||
| Q4 23 | — | — |
| Q4 25 | — | 0.4% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | 92.5% | 0.5% | ||
| Q3 24 | 143.9% | 0.3% | ||
| Q2 24 | — | 0.6% | ||
| Q4 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.29× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.42× | — | ||
| Q3 24 | -26.94× | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
